| IVBT Stock | | | USD 0 0.00 0.00% |
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innovation1 Biotech. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as
signals in bureau of labor statistics.
Innovation1 Biotech OTC Stock Z Score Analysis
Innovation1 Biotech's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Innovation1 Biotech Z Score | | | | 4.8 |
Most of Innovation1 Biotech's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovation1 Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
According to the company's disclosures, Innovation1 Biotech has a Z Score of 4.8. This is 28.89% lower than that of the Healthcare sector and 43.71% higher than that of the
Biotechnology industry. The z score for all United States stocks is 44.95% higher than that of the company.
Innovation1 Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovation1 Biotech's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Innovation1 Biotech could also be used in its relative valuation, which is a method of valuing Innovation1 Biotech by comparing valuation metrics of similar companies.
Innovation1 Biotech is currently under evaluation in z score category among its peers.
Innovation1 Fundamentals
About Innovation1 Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovation1 Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovation1 Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Innovation1 Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to
measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to
predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.